
Evidence for Brain Energy Metabolic Support with CNM-Au8 Treatment: Results from the **REPAIR Phase 2 Clinical Trials**

Robert Glanzman¹, MD FAAN, Chief Medical Officer, Jimin Ren², PhD, Richard B. Dewey, III MD², Austin Rynders¹, RN, Senior Director, Clinical Operations, Karen S. Ho¹ PhD MSc, Head, Translational Medicine Michael T. Hotchkin¹, Chief Development Officer, Richard B. Dewey, Jr.² MD, Benjamin Greenberg² MD ¹Clene Nanomedicine, Inc., ²University of Texas, Southwestern

CONCLUSION: The REPAIR clinical trials demonstrate brain target engagement with **CNM-Au8 treatment impacting brain energy metabolic support**





Baseline Visit ³¹P-MRS Scan

Clinic Visit Safety

Clinic Visit Safety

2° Endpoint | NAD⁺ & NADH Fraction

REPAIR Integrated Analysis

³¹P-MRS Average Change in Brain NAD & NADH (% Fraction)

Partial Volume Coil; % Fraction of NAD⁺ and NADH

Clinic Visit Primary Endpoint ³¹P-MRS Scan


Clinic Visit Follow-up ³¹P-MRS Scan

pairPD

INS

1° Endpoint | NAD⁺/NADH Change at Week 12¹

REPAIR Integrated Analysis ³¹P-MRS Change in Brain NAD⁺/NADH Ratio at End of Treatment Partial Volume Coil; Ratio of NAD⁺/NADH (% Fraction of NAD⁺, NADH Couple) **Primary Endpoint**, (Paired t-test), Mean ± SEM



Objective

Demonstration of CNS target engagement with ³¹P-magnetic resonance spectroscopy (³¹P-MRS)

Design


Open-label, dose blinded 12-week treatment (Enrolled: REPAIR-PD) n=13, REPAIR-MS, n=13)

Endpoints

 Primary: change of NAD⁺/NADH ratio based on pre-specified integrated analyses of PD & MS

¹NAD+/NADH ratio declines approximately 0.5% per decade in cross-sectional observational studies

Exploratory | Equilibration of Energetic Metabolites



cohorts

 Secondary: change of NAD⁺ and NADH fractions of NAD pool

Safety

- Well tolerated; 97% treatment compliance
- TEAEs were all mild-to-moderate severity and transient
- No SAEs

Acknowledgements: We are honored by the PD and MS study patients and their families for their support and willingness to engage in clinical research. We thank the site investigators for their research excellence and dedication to patients. We thank Jimin Ren, PhD and colleagues at the UTSW Advanced Imaging Research Center for development of the ³¹P-MRS imaging methodology.

